PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2128992
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2128992
Vitreoretinal Surgery Devices Market size was valued at US$ 780.1 Million in 2025, expanding at a CAGR of 4.8% from 2026 to 2033.
Vitreoretinal Surgery Devices Market consists of surgical systems, instruments, consumables, lighting devices, surgical fluids, silicone oil dispensers, and other products that are utilized for diagnosing, treatment, and management of retinal and vitreous disorders. They are used in procedures such as vitrectomy, retinal detachment surgery, diabetic retinopathy, macular surgery, and various others in the posterior segment. Increasing incidence of retinal disorders, aging population, diabetes, and increasing popularity of MIS are driving market growth.
Vitreoretinal Surgery Devices Market- Market Dynamics
Growing Burden of Retinal Disorders and Increasing Need for Surgical Eye Care
The increasing prevalence of diseases in the retina, eye disease related to diabetes and age-related eye diseases will be responsible for the growing demand for Vitreoretinal Surgery Devices. Numerous diseases treated with these vitrectomy and micro surgery techniques such as diabetic retinopathy, retinal diseases, macular diseases, bleeding of the vitreous humor, and retinal detachment. The elderly population is rising in size and the diseases such as age-related macular degeneration are common. In the U.S., for instance, 20 million (N.E.I. or National Eye Institute) people suffer from age-related macular degeneration (AMD) and 1.5 million of these individuals are at risk of losing their vision due to AMD. The AMD damages the retina and is a leading cause of vision loss in the United States of people older than 65 years. The other important demand driver is diabetes. DR escalate to more severe diabetic retinopathy which can require surgical interventions like vitrectomy, providing a market for surgical consumables, endo-illumination instruments, vitrectomy systems, and vitreoretinal devices.
The Global Vitreoretinal Surgery Devices Market is segmented on the basis of Product Type, Surgery Type, End User, Technology, and Region.
Based on the Product Type, the Vitrectomy Systems is an important part of the Vitreoretinal Surgery Devices Market due to increased preference for high-speed cutters, fluidics, small gauge instruments, illumination systems, and intra-operative pressure management. Modern day devices are engineered for the minimally invasive 25/27-gauge surgery system that was developed to make the incision small and the surgery process easy. In April 2025, Alcon launched its UNITY(R) Vitreoretinal Cataract System (VCS), which includes HYPERVIT(R) 30K 30,000-cuts-per-minute vitrectomy probe, in addition to Unity instrumentation system and intelligent fluidics system. Innovation was demonstrated in the vitrectomy-system segment as the system launched shipping to Australia, Europe, Japan and the U.S. from May 2025.
Technology, 25/27-Gauge Micro-incision Systems are rising in significance because they provide increasingly advanced surgical capabilities in a less invasive approach using smaller-gauge instruments. In October 2024, for instance, ZEISS announced the addition of its EVA NEXUS(TM) phacovitrectomy system, 27G ULTRA instruments for small-gauge surgery and TDC two-dimensional cutting technology up to 20,000 CPM to its DORC (diagonal optical resection) portfolio.
Vitreoretinal Surgery Devices Market- Geographical Insights
The North American vitreoretinal surgery devices market is expected to be a big market due to the presence of advanced ophthalmic infrastructure, high adoption of minimally invasive surgery, availability of specialists, and a high prevalence of retinal diseases. As an example, in 2021, the U.S. CDC's projections were that 9.6 million Americans had DR, with 1.84 million having vision-threatening DR (VTDR). The large patient population that requires retinal monitoring, advanced treatment, and the use of vitrectomy systems, endo-illumination instruments, surgical liquids and micro-incision instruments to perform said treatment is expected to drive demand.
The European market is also an important market in view of its ageing population, existing ophthalmology infrastructure and high volume of ophthalmic surgery. For example, Eurostat data for 2023 showed that over 5.0 million cataract surgeries were carried out in the EU, which is 1,118 surgeries per 100,000 people. Cataract surgery is different from vitreoretinal surgery, but the volume is impressive in terms of the size of Europe's ophthalmic surgical infrastructure and the presence of specialized surgical centers. Furthermore, WHO estimates that around 90 million Europeans are affected by vision impairment or blindness, which represents a justification for investing further in eye-care technologies and services.
The Vitreoretinal Surgery Devices Market is highly competitive with an emphasis on technology, with companies competing in the fast vitrectomy technique, small gauge instruments, advanced fluidics, real time intra-operative visualization, advanced illumination, surgical consumables and ophthalmic platform technology. Leading companies are Alcon, Carl Zeiss Meditec, DORC, Bausch + Lomb, Johnson & Johnson Vision, Topcon, Nidek, Hoya, Geuder, Oertli Instrumente and MedOne Surgical. As the vitreoretinal and cataract surgical units advance and integrate into one surgical platform, companies are seeking to boost operating room efficiency.
In May 2026, Bausch + Lomb Corporation announced the launch of its innovative dual-port vitrectomy cutter, Bi-Blade+, in Europe with the use of Bausch + Lomb's vision enhancement system, Stellaris. The product received FDA 510(k) approval for Bi-Blade+ and the latest iteration of Adaptive Fluidics technology, which is said to improve the flow rate and stability of IOP during vitreoretinal surgery.
In August 2025, ZEISS Medical Technology showcased a comprehensive retina-care workflow at EURETINA 2025, combining diagnostic, surgical, and digital technologies. In addition, ZEISS introduced the new ZEISS ARTEVO 850 and ARTEVO 750 eye systems with updated ZEISS CALLISTO eye software for Vitreoretinal and combined phacovitrectomy procedures into the DORC EVA NEXUS platform, respectively.